375 related articles for article (PubMed ID: 28807816)
1. mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.
Di Domenico F; Tramutola A; Foppoli C; Head E; Perluigi M; Butterfield DA
Free Radic Biol Med; 2018 Jan; 114():94-101. PubMed ID: 28807816
[TBL] [Abstract][Full Text] [Related]
2. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain.
Perluigi M; Pupo G; Tramutola A; Cini C; Coccia R; Barone E; Head E; Butterfield DA; Di Domenico F
Biochim Biophys Acta; 2014 Jul; 1842(7):1144-53. PubMed ID: 24735980
[TBL] [Abstract][Full Text] [Related]
3. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
[TBL] [Abstract][Full Text] [Related]
4. HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.
Barone E; Head E; Butterfield DA; Perluigi M
Free Radic Biol Med; 2017 Oct; 111():262-269. PubMed ID: 27838436
[TBL] [Abstract][Full Text] [Related]
5. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
6. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.
Caccamo A; Majumder S; Richardson A; Strong R; Oddo S
J Biol Chem; 2010 Apr; 285(17):13107-20. PubMed ID: 20178983
[TBL] [Abstract][Full Text] [Related]
7. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
8. Autophagic dysfunction in Alzheimer's disease: Cellular and molecular mechanistic approaches to halt Alzheimer's pathogenesis.
Uddin MS; Mamun AA; Labu ZK; Hidalgo-Lanussa O; Barreto GE; Ashraf GM
J Cell Physiol; 2019 Jun; 234(6):8094-8112. PubMed ID: 30362531
[TBL] [Abstract][Full Text] [Related]
9. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.
Di Domenico F; Coccia R; Cocciolo A; Murphy MP; Cenini G; Head E; Butterfield DA; Giorgi A; Schinina ME; Mancuso C; Cini C; Perluigi M
Biochim Biophys Acta; 2013 Aug; 1832(8):1249-59. PubMed ID: 23603808
[TBL] [Abstract][Full Text] [Related]
10. Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome.
Di Domenico F; Tramutola A; Barone E; Lanzillotta C; Defever O; Arena A; Zuliani I; Foppoli C; Iavarone F; Vincenzoni F; Castagnola M; Butterfield DA; Perluigi M
Redox Biol; 2019 May; 23():101162. PubMed ID: 30876754
[TBL] [Abstract][Full Text] [Related]
11. Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease.
Caccamo A; Belfiore R; Oddo S
Neurobiol Aging; 2018 Aug; 68():1. PubMed ID: 29729422
[TBL] [Abstract][Full Text] [Related]
12. Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.
Head E; Lott IT; Wilcock DM; Lemere CA
Curr Alzheimer Res; 2016; 13(1):18-29. PubMed ID: 26651341
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?
Cai Z; Zhao B; Li K; Zhang L; Li C; Quazi SH; Tan Y
J Neurosci Res; 2012 Jun; 90(6):1105-18. PubMed ID: 22344941
[TBL] [Abstract][Full Text] [Related]
14. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
[TBL] [Abstract][Full Text] [Related]
15. mTOR signaling and Alzheimer's disease: What we know and where we are?
Davoody S; Asgari Taei A; Khodabakhsh P; Dargahi L
CNS Neurosci Ther; 2024 Apr; 30(4):e14463. PubMed ID: 37721413
[TBL] [Abstract][Full Text] [Related]
16. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
[TBL] [Abstract][Full Text] [Related]
17. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease.
Armstrong RA
Folia Neuropathol; 2009; 47(4):289-99. PubMed ID: 20054780
[TBL] [Abstract][Full Text] [Related]
18. Molecular interplay between hyperactive mammalian target of rapamycin signaling and Alzheimer's disease neuropathology in the NS-Pten knockout mouse model.
Hodges SL; Reynolds CD; Smith GD; Jefferson TS; Nolan SO; Lugo JN
Neuroreport; 2018 Sep; 29(13):1109-1113. PubMed ID: 29965873
[TBL] [Abstract][Full Text] [Related]
19. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
20. Dihydrotanshinone I Increase Amyloid-β Clearance and Decrease Tau Phosphorylation via Enhancing Autophagy.
Bao Z; Zhang H; Jiao H; Chu X; Fu J; Wang L
Pharmacology; 2020; 105(5-6):311-319. PubMed ID: 32200384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
